Biotech & Pharma.T.A, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A,

BIB 77.21

-1.5%

Dec 18 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Steve Lokness who wrote (1896)	9/25/2007 11:20:29 PM
From: Jibacoa	Read Replies (1) of 3722

Steve, TWTI Also has been on a near term UT since July 24 when it had the spike on volume of 2,926,200 after it announced that the U.S. District Court in Wisconsin issued a patent opinion in its favor on the claim dispute it had with Digine. That UT has been preserved (the intraday break on Aug 14 doesn't count since it recovered well of the "panic selling". bigcharts.marketwatch.com There has been some insider buying in spite of the higher losses in the first 2Qs.( The EL for 2007 is around $0.60/shr vs. $0.42/shr in 2006 ) But revenues on the 2ndQ were a little better & the EL is less than it was a few weeks ago) This week the stock made a 5 Yrs H as it traded above its Dec 2004 H of $9.08 The all time H was $11.65 in June 2001 bigcharts.marketwatch.com CPHD's UT started on March 14 from the $8.50 level after it filed its annual report. The agreement with ABT last September, the purchase of Sangtec in Feb, the presentation at the AACC in July,the announcement in Aug of the purchase order for $200M of anthrax test cartridges for use on the BDS at the UPS & the fact that it has continued to trim its losses has helped it to keep the UT.(Also remember my comments back in April on the FDA approval of its test for MRSA.) Message 23469945 bigcharts.marketwatch.com It is due to present tomorrow at the UBS conference in NY & it will probably be able to go over last Wednesday H. GHDX Had an UT last Yr. from June to Dec (from the 10.90 to the 24.30 level. After the double top in Jan it retraced to the 14.75 level on May 18 It rallied from there up to the 22.25 on July 19, but it has been on a near term DT since then. It needs to close above the 21 level.Support is at 18.75 bigcharts.marketwatch.com It presented some posters at the ASCO Breast Cancer Symposium in Frisco earlier this month & also last week in Frisco the CEO presented at the ThinkEquity Partners 5th Growth Conference. It hasn't been able to cut its loss in spite of significant better revenues, but things are expected to get better in the pending 2 Qs for this Yr. & for 2008 the loss is expected to be cut by at least 75%. Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next